INDICATIONS:

Lorlatinib as monotherapy is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after: • Alectinib or Ceritinib as the first ALK inhibitor therapy; or • Crizotinib and at least one other ALK inhibitor. 

DOSAGE & ADMINISTRATION The recommended dose is 100 mg Lorlatinib taken orally once daily. Duration of treatment Treatment with Lorlatinib is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity. Delayed or missed doses If a dose of Lorlatinib is missed, then it should be taken as soon as the patient remembers unless it is less than 4 hours before the next dose, in which case the patient should not take the missed dose. Patients should not take 2 doses at the same time to make up for a missed dose. Dose modifications Dosing interruption or dose reduction may be required based on individual safety and tolerability. Lorlatinib dose reduction levels are summarized below: • First dose reduction: 75 mg taken orally once daily. •Second dose reduction: 50 mg taken orally once daily. Lorlatinib should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily

FIND A PRODUCT